New Century Financial Group LLC Has $304,000 Stake in argenx SE (NASDAQ:ARGX)

New Century Financial Group LLC reduced its position in argenx SE (NASDAQ:ARGX) by 4.5% in the 4th quarter, Holdings Channel reports. The firm owned 489 shares of the company’s stock after selling 23 shares during the quarter. New Century Financial Group LLC’s holdings in argenx were worth $304,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of the business. SG Americas Securities LLC boosted its position in shares of argenx by 6.2% during the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after acquiring an additional 21 shares in the last quarter. Profund Advisors LLC lifted its stake in argenx by 3.0% during the second quarter. Profund Advisors LLC now owns 973 shares of the company’s stock worth $418,000 after purchasing an additional 28 shares during the period. Raymond James Trust N.A. boosted its holdings in argenx by 6.0% during the third quarter. Raymond James Trust N.A. now owns 495 shares of the company’s stock valued at $268,000 after purchasing an additional 28 shares in the last quarter. Hantz Financial Services Inc. raised its holdings in shares of argenx by 8.9% in the 3rd quarter. Hantz Financial Services Inc. now owns 528 shares of the company’s stock worth $286,000 after buying an additional 43 shares in the last quarter. Finally, Aaron Wealth Advisors LLC lifted its position in shares of argenx by 10.1% during the 4th quarter. Aaron Wealth Advisors LLC now owns 489 shares of the company’s stock worth $301,000 after buying an additional 45 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on ARGX shares. Scotiabank raised shares of argenx from a “sector perform” rating to a “sector outperform” rating and upped their target price for the stock from $439.00 to $715.00 in a report on Tuesday, November 5th. Robert W. Baird cut argenx from an “outperform” rating to a “neutral” rating and increased their target price for the stock from $515.00 to $650.00 in a report on Friday, November 1st. Deutsche Bank Aktiengesellschaft lowered argenx from a “hold” rating to a “sell” rating in a research note on Friday, January 17th. JPMorgan Chase & Co. upped their price target on shares of argenx from $640.00 to $670.00 and gave the stock an “overweight” rating in a research report on Monday, November 4th. Finally, Raymond James restated a “strong-buy” rating and issued a $605.00 price objective on shares of argenx in a research report on Thursday, October 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, argenx currently has a consensus rating of “Moderate Buy” and an average price target of $658.39.

argenx Price Performance

Shares of NASDAQ:ARGX opened at $648.94 on Friday. The company has a market capitalization of $39.18 billion, a price-to-earnings ratio of -737.43 and a beta of 0.59. The firm’s 50 day simple moving average is $625.94 and its 200 day simple moving average is $562.96. argenx SE has a fifty-two week low of $349.86 and a fifty-two week high of $678.21.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $588.88 million for the quarter, compared to analysts’ expectations of $543.29 million. During the same period last year, the firm posted ($1.25) earnings per share. Equities research analysts expect that argenx SE will post 2.78 earnings per share for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.